A Revolution In Blood Glucose Monitoring For 460 Million+ People Living With Diabetes Worldwide

Introducing Opuz™: a world-first in blood glucose monitoring for people living with diabetes. Unlike any device currently on the market, Opuz™ is an entirely non-invasive, comfortable, pain-free and wearable device for people with diabetes. The ring connects to a smartphone application so wearers can monitor their condition at will with up-to-date data. The vision behind Opuz™ is to make life easier for the 460 million+ people living with diabetes worldwide.

Opuz™ is ground-breaking: a non-invasive, comfortable and pain-free ring that can be conveniently worn by adults with diabetes. The technology guiding the device is exceptional: Opuz™ tracks blood glucose levels by combining their proprietary algorithmic intelligence with bioimpedance measurements. CEO of Opuz™ Andrew Just has decades of experience with blue chip healthcare companies and confirms that the recent clinical study has solved “the most difficult technological challenge in being able to translate bioimpedance data into a blood glucose result”. “In 30 years of industry experience,” Just affirms, “this is the most exciting product I’ve seen.”

Development of Opuz™ began in 2019 and the prototype was completed in late 2020. Initially, the proof of concept was validated through an internal trial. The results far exceeded expectation: the accuracy was superior to a market leading continuous glucose monitoring (CGM) sensor. It was a milestone that meant the device was no longer just an idea, but a solution that could prove life changing. The team of scientists and engineers attracted investment which fast-tracked the development of the Opuz™ prototype. In a clinical study of the medical device* for potential use in management of type 2 diabetes*, participants were provided with a wearable Opuz™ prototype which consisted of a ring, watch and smartphone application comparing alongside two market-leading glucose monitoring methods. The study monitored users continuously over two weeks. Participants ranged in age, Body Mass Index (BMI), and ethnicity, and wore the device as they lived their normal lives over two weeks; a key differentiator from other early-stage device trials aiming to achieve the same results as Opuz™. This means that Opuz™ was tested through exposure to real-world variables, as opposed to emerging inventions that test their claims in controlled environments.

The clinical study results found Opuz™ to be the superior device for measuring blood glucose levels across the board. Andrew Just notes this is “ground-breaking” as the superior accuracy of Opuz™ has been demonstrated against the leading CGM device; without the pain, discomfort or inconvenience that people with diabetes are used to experiencing.

Unlike commonly used methods, Opuz™ is the first simple, non-invasive, comfortable wearable that brings peace of mind to those with diabetes, with 24/7 monitoring. (Andrew Just)

Just celebrates: “we are creating a new and better way for people to self-monitor their blood glucose levels without the hassle, pain and inconvenience of traditional blood glucose monitors”.

Study participant Dr Willis Davies lamented the regular discomfort he experiences in monitoring his blood glucose with a traditional finger prick test: “I find the whole process of pricking my finger uncomfortable; pretty intense.” Dr Davies’ experience with the Opuz™ prototype is testament to the value it can add to the lives of those with diabetes. Dr Davies said wearing the ring was convenient and projected that a future of checking his blood glucose with the Opuz™ system would involve “far less discomfort; far less hassle; far less of a process”. The significant improvement in comfort and convenience when measuring blood glucose levels was magnified by access to accurate and live data that was readily available:

That connection is really important. If you know that a high or a low is the result of something you have eaten that’s really helpful. I found out from the study that my [fasting] blood glucose measurements first thing in the morning were quite high.”  (Dr Willis Davies)

Access to live updates empowers people living with diabetes to understand how different lifestyle factors directly impact their blood sugar levels. Opuz™ seamlessly improves quality of life for those with diabetes, helps them manage their condition and empowers them to “live a healthier, happier life” (Just).

In sharing the clinical trial results, inventor and former CEO of Opuz™ Mobin Nomvar, confirms that Opuz™ has achieved a goal that many multinational tech and pharmaceutical giants have not: producing a convenient device that betters the lives of those with diabetes through a non-invasive and affordable CGM. Nomvar highlights: “we want users of Opuz™ to benefit greatly from our work”.

In proving the superior effectiveness of Opuz™, the team will be able to present a viable non-invasive, pain-free alternative to the market in the future. Additionally, the device is likely to be much more affordable in comparison with existing management options. With revolutionary technology and conclusive study results to support its value, Opuz™ is set to significantly improve the lives of those with diabetes; an offering the Opuz™ team is “very pleased with, and proud of” (Just).

*Using patent-pending technology.

About Opuz Pty Limited

Opuz is a wearable monitoring ring that is a revolution in diabetes technology.

In a recent clinical study Opuz demonstrated that it has the potential to replace both traditional and modern methods of blood glucose measurement.

How? Opuz is:

  • Convenient. Opuz is a continuous glucose measurement (CGM) ring that replaces traditional finger prick tests and CGM meters. Unlike current market leaders, Opuz is entirely pain free, non-invasive and involves no needles, accessories or mess.
  • Intuitive. The Opuz ring connects to a smartphone app via Bluetooth. Users can access up-to-date blood glucose (BG) data via the app to check their levels anywhere, anytime.
  • Precise. In a recent clinical study of Opuz for use in management of type 2 diabetes, the data collected by Opuz clearly proved to be more accurate than the leading CGM meter. In this way, Opuz also usurps wearable competitors.
  • Affordable. Opuz is estimated to more than halve current monitoring costs

We are currently working on developing our prototype into a ready for production model.

Register Interest